Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tassone P, Abbruzzese A, Tagliaferri P, Caraglia M. Correale P, et al. Among authors: caraglia m. Eur J Cancer. 2010 Jun;46(9):1703-11. doi: 10.1016/j.ejca.2010.03.005. Eur J Cancer. 2010. PMID: 20399639
Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rotonda MI, Leonetti C, Caraglia M, De Rosa G. Salzano G, et al. Among authors: caraglia m. Int J Pharm. 2011 Jan 17;403(1-2):292-7. doi: 10.1016/j.ijpharm.2010.10.046. Epub 2010 Nov 3. Int J Pharm. 2011. PMID: 21055454
Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.
Grieco P, Franco R, Bozzuto G, Toccacieli L, Sgambato A, Marra M, Zappavigna S, Migaldi M, Rossi G, Striano S, Marra L, Gallo L, Cittadini A, Botti G, Novellino E, Molinari A, Budillon A, Caraglia M. Grieco P, et al. Among authors: caraglia m. J Cell Biochem. 2011 Jan;112(1):341-53. doi: 10.1002/jcb.22933. J Cell Biochem. 2011. PMID: 21080343
Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes.
Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, Ascani R, La Rotonda MI, Abbruzzese A, Tagliaferri P, Caraglia M, De Rosa G. Marra M, et al. Among authors: caraglia m. Nanomedicine. 2011 Dec;7(6):955-64. doi: 10.1016/j.nano.2011.03.004. Epub 2011 Mar 29. Nanomedicine. 2011. PMID: 21453789
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients.
Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, Romano O, Abbruzzese A, Lamberti M, Luzzi L, Gotti G, Rotundo MS, Caraglia M, Tagliaferri P. Correale P, et al. Among authors: caraglia m. Cancer Biol Ther. 2011 Jul 15;12(2):112-8. doi: 10.4161/cbt.12.2.15722. Epub 2011 Jul 15. Cancer Biol Ther. 2011. PMID: 21525780 Free article. Clinical Trial.
544 results